|
Recent Publications |
|
|---|---|
|
Zhang X, Ciesielski M, Fenstermaker RA, Kaminski HJ, Kusner LL. The Presence of Survivin on B Cells from Myasthenia Gravis Patients and the Potential of an Antibody to a Modified Survivin Peptide to Alleviate Weakness in an Animal Model. J Immunol. 2020;205(7):1743-1751. |
|
|
Cron MA, Guillochon E, Kusner L, Le Panse R. Role of miRNAs in Normal and Myasthenia Gravis Thymus. Front Immunol. 2020;11:1074. |
|
|
Kusner LL, Yucius K, Sengupta M, et al. Investigational RNAi Therapeutic Targeting C5 Is Efficacious in Pre-clinical Models of Myasthenia Gravis. Mol Ther Methods Clin Dev. 2019;13:484-492. |
|
|
Punga AR, Kusner L, Berrih-Aknin S, Le Panse R. Editorial: Advances in Autoimmune Myasthenia Gravis. Front Immunol. 2020;11:1688. |
|
|
Guptill JT, Barfield R, Chan C, Russo MA, Emmett D, Raja S, Massey JM, Juel VC, Hobson-Webb LD, Gable K, Gonzalez N, Hammett A, Howard Jr, JF, Chopra M, Kaminski HJ, Siddiqi Z, Migdal M, Yi JS. Reduced plasmablast frequency is associated with seronegative myasthenia gravis. Muscle Nerve 2021;63:577-85. |
|
|
Guidon A. Muppidi S, Nowak RJ, Guptill JT, Hehir MK, Ruzhansky K, Burton LB, Post D, Cutter G, Conwit R, Mejia NI, Kaminski HJ, Howard, Jr. JF. Telemedicine visits in myasthenia gravis: Expert guidance and the myasthenia gravis core exam (MG-CE) Muscle Nerve 2021;64:270-76. |
|
|
Cleanthous S, Mork A-C, Regnault A Cano S, Kaminski HJ, Morel T. The development of a patient-centered outcome measure of myasthenia gravis (MG) symptoms: The MG Symptoms PRO. Oprhanet J Rare Dis 2021;16:457-471. |
|
|
Verschuuren J, Palace J, Murai H, Tannemaat M, Kaminski H, Bril V. Advances and ongoing research in treatment of autoimmune neuromuscular transmission diseases. Lancet Neurol 2022:21:189-202. |
|
|
Green JD, Macek M, International Myasthenia Gravis Genomics Consortium, Drachman DB, Traynor BJ. Analyses of a cohort of myasthenia gravis patients reveals new evidence for genetic contributions to the disease. PNAS 2022;119 e2108672119. |
|
|
Gutierrez G, Girma H, Kuhnell P, Macaluso M, Kaminski HJ. Impact of the Covid-19 epidemic on a US sample of patients with myasthenia gravis. Therap Adv Rare Dis 2022; 3:1-8. |
|
|
Kaminski HJ, Denk J. Corticosteroid resistance in myasthenia gravis. Front Neurology 2022 Apr 25;13:886625. doi: 10.3389/fneur.2022.886625. |
|
|
Forgash J., Chang Y.M., Mittelman N., Petesch S., Benedicenti L., Galban E., Hammond J., Glass E., Barker J., Shelton, G.D., Luo J., Garden O.A. (2021) Clinical features and outcome of acquired myasthenia gravis in 94 dogs. J. Vet. Intern. Med. 35:2315–2326. |
|
|
Leopardi V., Chang Y.M., Pham A., Luo J., Garden O.A. (2021) Infectious agents in the etiology of myasthenia gravis: a systematic review. Front. Neurol. 12:618021. (Luo J. and Garden O.A. share senior authorship) |
|
|
Barr C.A., Alvarado F., Chang Y.M., Luo J., Garden O.A. (2021) The impact of alfaxalone, propofol and ketamine on canine peripheral blood lymphocyte cytotoxicity in vitro. Res. Vet. Sci. 136:182-184. |
|
|
Wu Y., Chang Y.M., Lawson B.S., Galban E.M., Mittelman N.S., Benedicenti L., Petesch S.C., Carroll A.B., Punt J.A., Luo J., Garden O.A. (2021) Myeloid-derived suppressor cell and regulatory T cell frequencies in canine myasthenia gravis: A pilot study. Vet. J. 267:105581. (Luo J. and Garden O.A. share senior authorship) |
|
|
u Y., Luo J., Garden O.A. (2020) Immunoregulatory cells in myasthenia gravis. Front. Neurol. 11:593431. (Luo J. and Garden O.A. share senior authorship) |
|
| Alshaikh JT, Amdur R, Sidawy A, Trachiotis G, Kaminski HJ. Analysis of a national surgical database for myasthenia gravis patients undergoing thymectomy. Muscle Nerve 2016;53:370-4. | |
| Xie Y, Meng Y, Li H-F, Hong Y, Zhu X, Sun L, Yue Y-X, Gao X, Li Y, Wang S, Kusner LL, Kaminski HJ. GR gene polymorphism is associated with inter-subject variability in response to glucocorticoids in patients with myasthenia gravis. Europ J Neurol 2016;23:1372-9. | |
| Kaminski HJ. Seronegative myasthenia: A vanishing disorder? JAMA Neurology 2016;73:1055-6. | |
| Wolfe GI, Kaminski HJ, Inmaculada B. Aban IB, Minisman G. Hui-Chien Kuo H-C., …. Vincent A, Dias-Tosta E, Robin Conwit R, Odenkirchen J, Marx A, Sonett, JR, Jaretzki A, Newsom-Davis J, Cutter GR, MGTX Study Group. Randomized Trial of Thymectomy for Myasthenia Gravis. New Engl J Med 2016;375:511-522. | |
| Xie Y, Li H-F, Jiang B, Li Y, Kaminski HJ, Kusner LL. Plasma IL-17 levels stratify across myasthenia gravis patient subtypes. Cytokines (in press). | |
| Alshaikh JT, Amdur R, Sidawy A, Trachiotis G, Kaminski HJ. Analysis of a national surgical database for myasthenia gravis patients undergoing thymectomy. Muscle Nerve (in press). | |
| Burns TM, Sanders DB, Kaminski HJ, Wolfe GI, Narayanswami P. Two steps forward one step back; Mycophenolate mofetil use for myasthenia gravis in the United States. Muscle Nerve 2015;51: 635-37. | |
| Renton AE, Pliner HA, Provenzano C, Evoli A…Kaminski HJ…Drachman DB, Traynor BJ. A genome wide association study of myasthenia gravis. JAMA Neurol 2015;72:396-404. | |
| Kusner LL, Losen M, Vincent A, Lindstrom J, Tzartos S, Lazaridis K, Martinez-Martinez P. Guidelines for pre-clinical assessment of the acetylcholine receptor-specific passive transfer myasthenia gravis model — Recommendations for methods and experimental designs. Exp Neurology 2015;270:3-10. | |
| Losen M, Martinez-Martinez P, Molenaar PC, Lazaridis K, Tzartos S, Brenner T, Duan RS, Luo J, Lindstrom J, Kusner L. Standardization of the experimental autoimmune myasthenia gravis (EAMG) model by immunization of rats with Torpedo californica acetylcholine receptors--Recommendations for methods and experimental designs. Exp Neurol. 2015;270:18-28. | |
| Punga AR, Kaminski HJ, Richman DP, Benatar M. How clinical trials of myasthenia gravis can inform preclinical drug development. Exp Neurology 2015;270:78-81. | |
| Kusner LL, Kaminski HJ. Special issue on standardization of preclinical evaluation of animal models for myasthenia gravis. Exp Neurology 2015;270:1-2. | |
| Drachman D, Kaminski HJ. The neuromuscular junction as Achilles’ heel: Yet another autoantibody? Neurology 2014; 82:1942-43. | |
| Zhou Y, Kaminski HJ, Gong B, Cheng G, Feuerman JM, Kusner LL. Gene Expression Analysis of Differential Muscle Involvement by Antibody-Induced Experimentally Acquired Myasthenia Gravis. Invest Ophthalmol Vis Sci 2014; 55:4348-59. | |
| Kusner LL, Marx A, Kaminski HJ, Fenstermaker RA, Ciesielski MJ. Survivin as a therapeutic target for antibody-mediated autoimmunity. PLOS ONE 2014;9:e102231. | |
| Li Y, Tu Z, Quin S, Fung J, Kusner L, Kaminski HJ, Lu L, Lin F. Myeloid derived suppressor cells as therapy for experimental myasthenia gravis J Immunol 2014;193:2127-34. | |
| Sengupta M, Cheema A, Kaminski HJ, Kusner LL. Metabolomic response to corticosteroid treatment among patients with myasthenia gravis. PLOS ONE 2014;9:e102635 | |
